Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
June 20, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
May 15, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
May 10, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR...
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023 10:14 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is...
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
April 18, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
NXP800 demonstrated robust antitumor activity in two patient-derived xenograft (“PDX”) models of cholangiocarcinomaResearch conducted by investigators from the Mayo Clinic in Rochester, MN Fort...
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
April 10, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
March 17, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
March 10, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights
March 07, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
NXP800 Granted Fast Track Designation for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian CarcinomaENGOT and GOG Foundation to Lead the NXP800 Phase 1b Clinical Trial in Ovarian Cancer...